Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lipson

Showing results (181-190 of 205) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Cell|September 7, 2024
Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapyYash Chhabra, Mitchell E Fane, Sneha Pramod, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Cancer Immunology Research|June 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumorsHoward L Li, Soren Charmsaz, Chester Kao, et al.
The Journal of Clinical Investigation|July 17, 2019
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitisKarthik Suresh, Jarushka Naidoo, Qiong Zhong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous CancersKara M Schenk, Julie Stein Deutsch, Sunandana Chandra, et al.
Journal for Immunotherapy of Cancer|October 5, 2018
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumabNicolas A Giraldo, Peter Nguyen, Elizabeth L Engle, et al.
The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Journal for Immunotherapy of Cancer|April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinomaPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Nature Communications|April 21, 2025
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitorsChester Kao, Soren Charmsaz, Hua-Ling Tsai, et al.
Pageof 21

Showing results (181-190 of 205) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Cell|September 7, 2024
Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapyYash Chhabra, Mitchell E Fane, Sneha Pramod, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Cancer Immunology Research|June 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumorsHoward L Li, Soren Charmsaz, Chester Kao, et al.
The Journal of Clinical Investigation|July 17, 2019
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitisKarthik Suresh, Jarushka Naidoo, Qiong Zhong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous CancersKara M Schenk, Julie Stein Deutsch, Sunandana Chandra, et al.
Journal for Immunotherapy of Cancer|October 5, 2018
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumabNicolas A Giraldo, Peter Nguyen, Elizabeth L Engle, et al.
The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Journal for Immunotherapy of Cancer|April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinomaPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Nature Communications|April 21, 2025
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitorsChester Kao, Soren Charmsaz, Hua-Ling Tsai, et al.
Pageof 21